Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial

American Journal of Medicine

Volumn 129, Issue 9, 2016, Pages 1002-1005

  Vaduganathan, Muthiah ^a   Cannon, Christopher P ^a,b   Cryer, Byron L ^c   Liu, Yuyin ^b,d   Hsieh, Wen Hua ^b   Doros, Gheorghe ^b,d   Cohen, Marc ^e   Lanas, Angel ^f   Schnitzer, Thomas J ^g   Shook, Thomas L ^h   Lapuerta, Pablo ⁱ   Goldsmith, Mark A ^j   Laine, Loren ^k,l   Bhatt, Deepak L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d BOSTON UNIVERSITY   (United States)

^e NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^f UNIVERSITY OF ZARAGOZA   (Spain)

^g NORTHWESTERN UNIVERSITY   (United States)

^h PAREXEL INTERNATIONAL   (United States)

ⁱ LEXICON PHARMACEUTICALS INC   (United States)

^j Department of Structural Biology   (United States)

^k YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

more..

Author keywords

Acute coronary syndrome; Bleeding; Clinical outcomes; Clinical trials; Coronary artery disease; Percutaneous coronary intervention; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; OMEPRAZOLE; PLACEBO; ANTITHROMBOCYTIC AGENT; PROTON PUMP INHIBITOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR RISK; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DUAL ANTIPLATELET THERAPY; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; UPPER GASTROINTESTINAL BLEEDING; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOUBLE BLIND PROCEDURE; GASTROINTESTINAL HEMORRHAGE; MULTICENTER STUDY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ASPIRIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; GASTROINTESTINAL HEMORRHAGE; HUMANS; OMEPRAZOLE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84990062811     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2016.03.042     Document Type: Article

References (17)

1. 1 Eikelboom, J.W., Mehta, S.R., Anand, S.S., Xie, C., Fox, K.A., Yusuf, S., Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114 (2006), 774–782.
2. 2 Bhatt, D.L., Cryer, B.L., Contant, C.F., et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363 (2010), 1909–1917.
3. 3 Vardi, M., Cryer, B.L., Cohen, M., et al. The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial. Aliment Pharmacol Ther 42 (2015), 365–374.
4. 4 Southworth, M.R., Temple, R., Interaction of clopidogrel and omeprazole. N Engl J Med, 363, 2010, 1977.
5. 5 Shah, N.H., LePendu, P., Bauer-Mehren, A., et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One, 10, 2015, e0124653.
6. 6 Sherwood, M.W., Melloni, C., Jones, W.S., Washam, J.B., Hasselblad, V., Dolor, R.J., Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: A systematic review. J Am Heart Assoc, 4, 2015, e002245.
7. 7 Frelinger, A.L. 3rd, Lee, R.D., Mulford, D.J., et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol 59 (2012), 1304–1311.
8. 8 Frelinger, A.L. 3rd, Bhatt, D.L., Lee, R.D., et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 61 (2013), 872–879.
9. 9 Banerjee, S., Weideman, R.A., Weideman, M.W., et al. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol 107 (2011), 871–878.
10. 10 Depta, J.P., Bhatt, D.L., Omeprazole and clopidogrel: should clinicians be worried?. Cleve Clin J Med 77 (2010), 113–116.
11. 11 Olsen, A.S., Lindhardsen, J., Gislason, G.H., et al. Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study. BMJ, 351, 2015, h5096.
12. 12 Vaduganathan, M., Bhatt, D.L., Revisiting the clopidogrel-proton pump inhibitor interaction: from bench to bedside. Circ Cardiovasc Interv, 8(10), 2015, 10.1161/CIRCINTERVENTIONS.115.003208.
13. 13 de Jong, H.J., Korevaar, J.C., van Dijk, L., Voogd, E., van Dijk, C.E., van Oijen, M.G., Suboptimal prescribing of proton-pump inhibitors in low-dose aspirin users: a cohort study in primary care. BMJ Open, 3(7), 2013, 10.1136/bmjopen-2013-003044.
14. 14 Vaduganathan, M., Bhatt, D.L., Cryer, B.L., et al. Proton-pump inhibitors reduce risk of gastrointestinal events regardless of aspirin dose in patients requiring dual antiplatelet therapy: Insights from the COGENT trial. J Am Coll Cardiol 67 (2016), 1661–1671.
15. 15 Bhatt, D.L., Scheiman, J., Abraham, N.S., et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 118 (2008), 1894–1909.
16. 16 Abraham, N.S., Hlatky, M.A., Antman, E.M., et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 122 (2010), 2619–2633.
17. 17 Moukarbel, G.V., Bhatt, D.L., Antiplatelet therapy and proton pump inhibition: clinician update. Circulation 125 (2012), 375–380.